Nuvectis Pharma, Inc. 8-K

What Happened

• On February 11, 2026, Nuvectis Pharma, Inc. announced a corporate update and released its financial results for the fiscal year ended December 31, 2025. The company furnished a press release as Exhibit 99.1 to the Form 8-K. The Form 8-K states the information (including Exhibit 99.1) is furnished, not filed, and therefore is not subject to Section 18 liability or incorporated by reference into other Securities Act filings unless expressly stated.

Key Details

• Filing date: February 11, 2026 (Form 8-K Items 2.02 and 9.01).
• Reporting period: fiscal year ended December 31, 2025.
• Exhibit 99.1: press release announcing the corporate update and FY2025 financial results (furnished).
• Exhibit 104: cover page interactive iXBRL data file included.

Why It Matters

• This 8-K is the company’s official disclosure that FY2025 results are available; investors should review the furnished press release (Exhibit 99.1) for revenue, earnings, cash position, and any management commentary or guidance. Because the release is furnished rather than filed, it has different legal treatment (not subject to Section 18 liabilities and not automatically incorporated by reference into other filings). For full financial detail and audited statements, investors should also consult the company’s forthcoming periodic filings (e.g., Form 10-K) or the press release itself.